Drugs / SIG001
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07486700 | Mar 2026 → Apr 2028 expected | neoplasm | Peking University | Not yet recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04541628 | Sep 2020 → Oct 2022 | hemophilia A | Eli Lilly and Company | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SIG-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04541628 ↗ |
| Modality | Cell therapy | “encapsulated allogeneic cell therapy” NCT04541628 ↗ |
| Route | Other | “Laparoscopic administration of SIG-001 spheres” NCT04541628 ↗ |